

Cancer	Trial Name	Key inclusion criteria	Treatment	Location	Coordinators
Endometrial Cancer	STATEC	High risk apparent FIGO stage I endometrial carcinoma i.e.: • Grade 3 endometrioid or mucinous OR • High grade serous, clear cell, undifferentiated or dedifferentiated or mixed cell adenocarcinoma or carcinosarcoma	Hysterectomy BSO & randomised to ± lymphadenectomy Arm 1 node negative: brachytherapy Arm 1 node positive & Arm 2: brachytherapy plus adjuvant chemo	Westmead	Kate Campbell T. 8890 6347 / Page 8345 Kate.Campbell1@health.nsw.gov.au
	Takeda <i>Closing September 2018</i>	Recurrent/metastatic endometrial cancer Measurable disease At least 1 line of systemic treatment No previous weekly paclitaxel	Weekly paclitaxel ± mTOR1/2 inhibitor	Westmead	Kate Campbell
Cervical Cancer	INCAGN01876	Recurrent Locally advanced or Metastatic ECOG 0 or 1 Received at least 1 prior line of platinum therapy Measurable disease, 1	Phase 1/2 - Expansion? INCAGN01876 = Anti-GITR antibody	Blacktown	Rebecca Hinshelwood Na Li William d'Avigdor
Ovarian Cancer	ATHENA	Newly diagnosed Stage III-IV high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer Completed 1st line platinum-based chemo & surgery with CR or PR No evidence of progression or rising CA-125 at any time during front-line treatment Excluded: pure sarcomas or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors. Mixed mullerian /carcinosarcomas are allowed.	Rucaparib and Nivolumab as maintenance treatment Double-blind placebo controlled (10% chance of double placebo)	Westmead	Kate Campbell
	CANTRIXIL <i>ON HOLD until Sept</i>	Recurrent or persistent ovarian cancer At least 2 lines systemic treatment incl. adjuvant ECOG 01-2 ≥2 previous lines of treatment, platinum resistance	Phase 1b - expansion - fixed dose 200mg Weekly Cantrixil IP Requires intraperitoneal port ± IV chemo at investigator's discretion after cycle 2	Westmead	Kate Campbell
	ECHO	Randomised, controlled trial of exercise during chemotherapy Patients commencing first line treatment for ovarian cancer	Experimental Arm: Exercise regimen by Exercise Physiologist Control Arm: usual care alone.	Westmead	Kate Campbell
	JTJN <i>All cohorts on hold awaiting interim analysis results</i>	Recurrent HGSO, primary peritoneal or fallopian tube cancer Measurable disease CNS recurrence free for 1 year Cohort 1 & 2: platinum resistant, BRCA negative Cohort 3: Platinum resistant, BRCA positive, prior PARP inhibitor Cohort 4: Platinum refractory, all comers	Prexasertib (CHK2 inhibitor) Q2W (iv) until PD	Westmead	Kate Campbell
Vulvar Cancer	AOCS2	Nonmucinous epithelial ovarian Must have >1cm ² fixed tissue available Read and speak English	Biobanking & blood sample Epidemiologic questionnaire	Westmead Blacktown	Nik Nevins T: 8890 5840/ 0431 513 249 nikilyn.nevins@health.nsw.gov.au
	INOVAte	Epithelial ovarian >18years Any stage, any grade	Biobanking & molecular testing	Westmead Blacktown	Nik Nevins
	Sentinel Node Audit MK3475-158	Unifocal SCC less than 4cm in greatest dimension Depth of invasion greater than 1mm Tumour does not involve urethra, anus or middle 1/3 of vagina Recurrent/metastatic Vulvar cancer	Surgical sentinel node resection Pembrolizumab	Westmead Blacktown	Kate Campbell
Cancer of unknown primary	SUPER	Any cancer of UNKNOWN primary >18yrs ; must read and speak English Less than 6 months of treatment	Questionnaires, blood sample and permission to access tissue Molecular testing for actionable mutations and site of origin	Westmead Blacktown Nepean	Nik Nevins Lisa Kay
	VESPA	confirmed diagnosis of gynaecological, rectal or anal cancer receiving pelvic external beam RT, with curative intent (both primary treatment and neo/adjuvant treatment). Not using oral HRT	Vaginal oestriol, twice weekly for 1 year	Westmead Nepean	Kate Campbell Shamira Cross T: 0423 850 554 Shamira.Cross@health.nsw.gov.au
	IMP4297	Advanced Solid Tumors ECOG 0 or 1 No prior PARP therapy Measurable disease No active or untreated brain metastasis	Phase 1 - expansion IMP4297= oral PARP inhibitor	Blacktown	Rebecca Hinshelwood Na Li William d'Avigdor
	GynBioBank	>18yrs known or investigated for gynae cancer	Consent for tissue use, medical record access and blood sample	Westmead Blacktown	Nik Nevins